Key result
Cyproheptadine provided marked improvement and resolution of anginal symptoms in a patient with refractory vasospastic angina unresponsive to conventional medical therapy.
Why the study?
When vasospastic angina is refractory to conventional medications, unconventional treatment modalities targeting mediators like serotonin may be needed for symptomatic relief.
Does cyproheptadine improve symptoms in a patient with refractory vasospastic angina?
Case Report (n=1)
No
Does cyproheptadine improve symptoms in a patient with refractory vasospastic angina?
Cyproheptadine, a serotonin receptor antagonist, may provide symptomatic relief in patients with vasospastic angina refractory to conventional medical therapy.
Hypothesis-generating for refractory vasospastic angina; should not change practice pending controlled trials.
Vasospastic angina (VSA) is the spasm of coronary arteries causing transient myocardial ischemia. VSA is commonly managed with antispasmodic medications including calcium-channel blockers (CCB) and nitrates. When vasospasm is refractory to conventional medications, unconventional treatment modalities may be used for symptomatic relief (Tandon et al., 2019 Feb) [1]. There are several mediators of vasospasm, with serotonin playing a major role. Serotonin is a product of platelet aggregation and has multiple effects on the endothelium, which forms the basis of an unconventional treatment modality that may be used for symptomatic relief of VSA. In this case, a 44 year old female with a history of coronary artery disease (CAD) status post coronary artery bypass graft (CABG) with recent drug-eluting stent (DES) placement was admitted for shortness of breath and chest pain, found to have a positive stress echocardiogram (Echo), and had unremarkable coronary angiography. Given persistent symptoms while on optimal medical therapy and with negative coronary angiography, the diagnosis of refractory VSA was made. Patient was started on a serotonin receptor blocker with improvement of her symptoms.
No takes yet. Share an insight, caveat, or question.
Song et al. (2021) conducted a case report in Refractory vasospastic angina (n=1). Cyproheptadine was evaluated on Improvement in anginal symptoms. Cyproheptadine provided marked improvement and resolution of anginal symptoms in a patient with refractory vasospastic angina unresponsive to conventional medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: